ripasudil
Selected indexed studies
- Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: Safety, Efficacy, and Patient Selection. (Clin Ophthalmol, 2020) [PMID:32440089]
- An update on ripasudil for the treatment of glaucoma and ocular hypertension. (Drugs Today (Barc), 2020) [PMID:33025953]
- Ripasudil does not induce phospholipid accumulation in human corneal epithelial cells. (Exp Eye Res, 2025) [PMID:40120926]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: Safety, Efficacy, and Patient Selection. (2020) pubmed
- An update on ripasudil for the treatment of glaucoma and ocular hypertension. (2020) pubmed
- Ripasudil does not induce phospholipid accumulation in human corneal epithelial cells. (2025) pubmed
- Ripasudil hydrochloride hydrate: targeting Rho kinase in the treatment of glaucoma. (2017) pubmed
- Neuroprotective effect of ripasudil on retinal ganglion cells via an antioxidative mechanism. (2025) pubmed
- Ripasudil-Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials. (2023) pubmed
- Topical Ripasudil for the Treatment of Primary Corneal Endothelial Degeneration in Dogs. (2022) pubmed
- Topical Ripasudil for the Treatment of Segmental Corneal Edema: A Case Series. (2023) pubmed
- Ripasudil in a Model of Pigmentary Glaucoma. (2020) pubmed
- Netarsudil v/s Ripasudil: The battle of supremacy between two ROCKS-I (rho kinase inhibitors). (2025) pubmed